March 10, 2025 4:32pm

Indexes and stocks fell sharply on Monday as recession fears tied to President Trump’s tariffs pressure indexes and equities as investors wait for new economic data, especially on inflation on Wednesday

Glaring selective sector BUYs, even though earnings season has yet to complete after 5 negatives out of 6 closes for new month of March

Beam Therapeutics (BEAM) financing update – Dropped -$2.79 or -9.80% to $25.69 after an offering of 16,151,686 shares priced at $28.48 per share – talk about a decline from morning session!

I say today what others won't, so you can do what others can't!

Never leave an investor uninformed! 

 

On point, short on words, long on facts and being judicious!

My mission is to provide clear, actionable guidance on a regular basis to help investors and traders navigate the uncertain and often irrational financial markets. We put hours of effort into creating our reports, while leveraging my 40 years of operating and research experiences to analyze the key market-moving events and distill that into a cogent outlook.

 

RegMed Investors’ (RMi) pre-open: opportunity in uncertainty? … https://www.regmedinvestors.com/articles/13833

Beam Therapeutics (BEAM) an offering of 16,151,686 shares priced at $28.48 per share … https://www.regmedinvestors.com/articles/13832

 

Friday night’s RegMed Investors (RMi) Closing Bell: a dine and dash week ending … https://www.regmedinvestors.com/articles/13831

RegMed Investors (RMi) Research Note: The clock continues to tick down on Harvard Apparatus GT (OTCQB: HRGN) … https://www.regmedinvestors.com/articles/13812

 

Monday: The Dow closed DOWN -890.01 points or -2.08%, the S&P closed DOWN -155.63 points or -2.69% while the Nasdaq closed DOWN -727.90 points or -4%

  • Last week, the S&P 500 lost 3.1% for its worst weekly mark since September, the Dow fell 2.4%, while the Nasdaq shed 3.5%.
  • Over the past month, the S&P 500 and Nasdaq are down 6% and 9%, respectively, while the Dow is down 4.5%.

Henry’omics: We need to more than consider the economic environment - rising rates and inflation to comprehend the micro re “our” universe of cell and gene therapy companies

  • Coming attractions or subtractions: the February consumer price index, or CPI, release is slated for Wednesday, followed by the producer price index, or PPI, on Thursday.

Monday’s advance/decline line opened with a negative 1 incliner, 29 decliners and 5 flats ending with a negative close of 3 incliners, 31 decliners and 1 flat

  • The sector is STUCK in an oversold level

Metrics:  Monday, the IBB was down -1.11 %, the XBI was down -1.06% while the VIX was up +4.59 points or +19.65% at 27.94

 

As compared to … Friday: The Dow closed UP +222.64 points or +0.52%, the S&P closed UP +31.68 points or +0.55% while the Nasdaq closed UP +126.97points or +0.70%

  • Indexes shook-off a weaker-than-expected jobs report raising further concerns about an economic softening which sent Treasury yields lower
  • All 3 of the market averages closed the trading week lower           

Henry’omics: We need to more than consider the economic environment - rising rates and inflation to comprehend the micro re “our” universe of cell and gene therapy companies

  • A gain of 151,000 in nonfarm payrolls for February. Average hourly earnings rose 0.3% in February and were up 4% on an annual basis. The jobs report also indicated that the unemployment rate edged higher to 4.1% as household employment dipped.

Friday’s advance/decline line opened with a positive 19 incliner, 14 decliners and 2 flats ending with a negative close of 14 incliners, 17 decliners and 4 flats

Metrics:  Friday, the IBB was up +0.74%, the XBI was up +0.24% while the VIX was down -1.28 points or -5.15% at 23.59

 

Q1/25 – March, 1 positive and 5 negative closes

  • February – 12 holiday, 11 negative and 7 positive closes
  • January - 2 holidays, 1 market close, 10 negative and 10 positive closes

Q4/24 –

  • December - 1 holiday, 6 positive and 15 negative closes
  • November – 1 holiday, 10 negative and 10 positive closes              
  • October: 8 positive and 15 negative sessions

 

Monday’s Closing UP (3 of 3)

  • Moderna (MRNA +$0.35 after Friday’s +$1.31),
  • Brainstorm Cell Therapeutics (BCLI +$0.03),
  • Harvard Apparatus RT (OTCQB: HRGN +$0.0120 with 1 share traded after Friday’s $0.00)

Flat (1)

  • Homology Medicine (FIXX)

Monday’s Closing DOWN (10 of 31):

  • Alnylam Pharmaceuticals (ALNY -$11.45 after Friday’s -$3.61)
  • Beam Therapeutics (BEAM -$2.79 after Friday’s +$1.23),
  • CRISPR Therapeutics (CRSP -$2.19 after Friday’s +$2.22),
  • Ionis Pharmaceuticals (IONS -$1.59 after Friday’s -$0.58),
  • Ultragenyx Pharmaceuticals (RARE -$1.12 after Friday’s -$1.40),
  • Lenz Therapeutics (LENZ -$1.10 after Friday’s +$0.91),
  • BioLife Solutions (BLFS -$0.97 after Friday’s -$0.97)
  • Intellia Therapeutics (NTLA -$0.89 after Friday’s +$0.45),
  • Vericel (VCEL -$0.76 after Friday’s +$0.80),
  • AxoGen (AXGN -$0.56)

 

The BOTTOM LINE: New week, the 2nd of March began with a diving/negative market and a decimated sector.

  • Last Friday, 3/7 – the 5th NEGATIVE session in the week intermingled by 1 POSITIVE (Wednesday) close in a new month of March … so, what moves stock pricing?

 

“I hate to be so negative or contrarian but, this is a NO spin zone and truth is its product; I can always be WRONG but, I am mostly EARLY!”

  • If I have learned one thing as a former research analyst in a venture and public fund, operating executive, x-FBI, x-military officer and an adjunct (MBA) business school professor now a journalist; my life and your portfolio are largely tied to knowledge of price movements and questioning pricing targets and more.
  • I don’t have much to write/say other than “electronic trading and uncle algo” slipped out the back door reaping sector disharmony and then popped right back for some profiteering.

 

Earnings are here … from Q4/24 and FY24 … my view will follow, has been busy and personally eventful!

  • Caribou Biosciences (CRBU) – Monday, 3/10
  • Agenus (AGEN) – Tuesday, 3/11
  • Voyager Therapeutics (VYGR) - Tuesday, 3/11
  • Sangamo Therapeutics (SGMO), Monday, 3/17

 

March ‘25: understand the “flow” …

  • 3/10 – Monday closed negative with 3 positive, 31 negative and 1 flat
  • 3/7 - Friday closed negative with 14 positive, 17 negative and 4 flats
  • 3/6 – Thursday closed negative with 16 positive, 18 negative and 1 flat
  • 3/5 – Wednesday closed positive with 25 positive, 9 negative and 1 flat
  • 3 /4 – Tuesday closed negative with 15 positive, 18 negative and 2 flats
  • 3/3 – Monday closed negative with 2 positive, 31 negative and 2 flats

 

Big Point to remember “Think about it; the biggest problem the cell and gene therapy sector it’s all to the future …  99% of them have no earnings!

  • If rates are higher for longer, that means that sector companies will continue to struggle or be unable to raise capital and therefore be subject to debt servicing firms!”
  • 2024 saw very little life IPOs (initial public offering) market and secondaries – I have seen private investments, mortgages, sell-offs, as companies deferred and struggle to gain further market access i.e., public. <Me>

What could 2025 have in store for the capital access space?

  • "You'll see a number of cell and gene therapy comandantes drive for secondaries – they’re desperate for cash, but I do think a lot of cell and gene therapy sector companies NEED to be focused on what is driving their own growth —they're focused on a lot of change BUT … that's happening in pipelines … capital expansion is second.

 

Why do I keep repeating, so investors can make the connection …

The top three (3) performing in the session:   

  • Monday: Moderna (MRNA), Brainstorm cell Therapeutics (BCLI) and Harvard Apparatus RT (OTCQB: HRGN)
  • Friday: Moderna (MRNA), CRISPR Therapeutics (CRSP) and Beam Therapeutics (BEAM)

The worst three (3) in the session: 

  • Monday: Alnylam Pharmaceuticals (ALNY), Beam Therapeutics (BEAM) and CRISPR Therapeutics (CRSP)
  • Friday: Alnylam Pharmaceuticals (ALNY), Blueprint Medicine (BPMC) and Ultragenyx Pharmaceuticals (RARE)

 

Welcome to my world of defining the “grey’ in our universe!

  • Right up front, “I also hate to be so negative or contrarian but, this is a NO spin zone and facts are its product; I can always be WRONG but … I am mostly EARLY!”

 

Opinions expressed are those of the author and are subject to change, and not intended to be a forecast of future events, a guarantee of future results, nor investment advice. Whether information or intelligence is good, bad, or somewhere in between; I put into context what is relevant and useful for investors.  All investments are subject to risks. Investors should consider investment objectives.

Henry McCusker, the editor, and publisher of RegMed Investors does not hold or have positions in securities referred to in this publication. Regulation Analyst Certification (Reg AC): The research analyst primarily responsible for the content of this report certifies the following under Reg AC: I hereby certify that all views expressed in this report accurately reflect my personal views about the subject company or companies and it’s or their securities.

I also certify that no part of my compensation was, is or will be, directly or indirectly, related to the specific recommendations or views expressed in this report.